Evercore ISI Remains a Hold on Sarepta Therapeutics (SRPT)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Clark-Gartner covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Rocket Pharmaceuticals, and Ascendis Pharma. According to TipRanks, Clark-Gartner has an average return of 4.1% and a 45.16% success rate on recommended stocks.
In addition to Evercore ISI, Sarepta Therapeutics also received a Hold from Goldman Sachs's Salveen Richter in a report issued today. However, on the same day, TD Cowen maintained a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
What Are the 2 Top Artificial Intelligence (AI) Stocks to Buy Right Now?
Key Points Spending on AI hardware and devices is on pace to jump impressively in 2025, which explains why Taiwan Semiconductor Manufacturing is growing sales at a healthy pace. An acceleration in AI software and services spending has led to an improvement in the growth rate of cloud communications specialist Twilio. 10 stocks we like better than Taiwan Semiconductor Manufacturing › A lot of money is being spent on artificial intelligence (AI) hardware and software now as organizations and governments across the globe look to benefit from the efficiency and productivity gains that this technology can deliver. Market research firm Gartner expects spending on generative AI will jump by 76% in 2025 to a whopping $644 billion. That's why it is a good time to take a closer look at two names that are benefiting from the rapid growth in AI spending in different areas. These companies are already delivering healthy growth and are trading at attractive valuations, so buying them right now could be a smart move. 1. Taiwan Semiconductor Manufacturing Taiwan Semiconductor Manufacturing (NYSE: TSM) is right in the middle of the AI revolution as it fabricates the high-end chips that go into devices ranging from data centers to smartphones to personal computers to cars. It's the largest third-party chip foundry in the world by far. Gartner points out that 80% of generative AI spending this year will be on hardware products, including both devices and servers. TSMC is already benefiting from this opportunity. The foundry giant's revenue in the first seven months of 2025 increased by 38% year over year. That impressive growth can be attributed to robust chip demand from top customers such as Nvidia, Apple, AMD, and Broadcom. The strong end-market demand led TSMC to increase its 2025 revenue growth guidance to 30% from its earlier expectation of growth in the mid-20% range. However, don't be surprised to see the Taiwan-based company exceeding even that upgraded target thanks to its AI-related catalysts. For instance, Counterpoint Research is expecting a 68% spike in sales of generative AI-capable smartphones in 2025. Apple, which is one of TSMC's largest customers, reported a 13.5% jump in its iPhone revenue in its most recently reported fiscal quarter. Importantly, Apple is expecting sales growth in the mid to high single-digit percentages in the current quarter, suggesting that it could witness another period of robust iPhone sales ahead of the holiday season. Moreover, TSMC's relationship with smartphone processor giant Qualcomm should pave the way for the company to grow its footprint in the smartphone market. On the other hand, TSMC's relationships with the leading AI chip designers and its focus on expanding its manufacturing capacity to serve this fast-growing market will set the stage for further healthy sales growth. The diversity of its customer base helps explain why the foundry's revenue is anticipated to increase at healthy double-digit percentages over the next couple of years as well. However, TSMC could end up doing better than that over the long run thanks to its improving share of the Foundry 2.0 market, which is expected to generate $298 billion in revenue this year. IDC expects Foundry 2.0 to grow at an annualized rate of 10% through 2029, and TSMC has been able to expand its market share in the space thanks to its focus on advanced chip packaging. As such, TSMC seems capable of outperforming expectations in the long run, and that's why buying the stock while it is trading at an attractive 24 times forward earnings (a discount to the tech-laden Nasdaq-100 index's multiple of 30) looks like the right thing to do. 2. Twilio Spending on generative AI services and software is also taking off as organizations and people adopt more applications to automate processes and increase productivity. According to estimates from Gartner, in 2025, total spending on AI services and software could jump by 119% to almost $65 billion. Twilio (NYSE: TWLO), a cloud communications specialist, is witnessing a healthy acceleration in growth thanks to the adoption of AI tools in its industry. Twilio's application programming interfaces (APIs) enable its clients to stay in touch with their customers through multiple channels such as text, voice, email, chat, and video. The company offers AI tools that allow its clients to build voice AI solutions such as AI agents to elevate the customer service experience, along with AI-powered marketing tools to improve conversion. The company's AI tools are helping it close bigger deals with customers. Twilio says that it saw a 57% year-over-year increase in the number of communications deals valued at $500,000 or more in the second quarter of 2025. The company's active customer accounts increased by 10% from the year-ago period, compared to a 4% increase in the same period last year. Spending by Twilio's established customers improved as well. This is evident from an increase of 5 percentage points in its dollar-based net expansion rate to 108%. (That metric compares the spending of active customers in a quarter to the same cohort's spending in the year-ago period.) Not surprisingly, Twilio has increased its organic revenue growth estimate for 2025 by 1.5 percentage points. It could, however, end up doing better than that thanks to its accelerating customer base growth as well as the cross-selling opportunities that its AI solutions are creating. Analysts covering the company are encouraged by its improving growth profile, and have raised their expectations for it. Finally, this cloud stock is trading at just 3 times sales, a slight discount to the S&P 500's sales multiple. Investors, therefore, can get a good deal on an AI stock that seems capable of flying higher in the long run. Should you buy stock in Taiwan Semiconductor Manufacturing right now? Before you buy stock in Taiwan Semiconductor Manufacturing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Taiwan Semiconductor Manufacturing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Apple, Nvidia, Qualcomm, Taiwan Semiconductor Manufacturing, and Twilio. The Motley Fool recommends Broadcom and Gartner. The Motley Fool has a disclosure policy. What Are the 2 Top Artificial Intelligence (AI) Stocks to Buy Right Now? was originally published by The Motley Fool Sign in to access your portfolio
Associated Press
7 hours ago
- Associated Press
SRPT FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - August 15, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the 'Class Period'), of the important August 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sarepta securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Sarepta class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (3) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (4) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Sarepta class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
Business Wire
9 hours ago
- Business Wire
SRPT Deadline: Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025. Sarepta is a commercial-stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Misled Investors Regarding its Business Operations. According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (3) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (4) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Sarepta Therapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 25, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
